Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -7.62% is 100% above its 5-year average of -3608.51%, near the high end of its 5-year range (-30838.89%–3.65%).
99.93% above its 12-month average of -10302.25%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2025 (2026-03-31): -71.50%.
EBITDA MARGIN
-7.62%
EBITDA MARGIN AVG TTM
-10302.25%
EBITDA MARGIN AVG 3Y
-6471.31%
EBITDA MARGIN AVG 5Y
-3608.51%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+99.93%
CURRENT VS 3Y AVG
+99.88%
CURRENT VS 5Y AVG
+99.79%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Paranovus Entertainment Technology Ltd.
Market Cap
$3.28M
EBITDA Margin
-7.62%
TTM Avg
-10302.25%
3Y Avg
-6471.31%
5Y Avg
-3608.51%
Market Cap
$3.30M
EBITDA Margin
-2774.55%
TTM Avg
-3680.87%
3Y Avg
-3159.91%
5Y Avg
-3026.36%
Market Cap
$3.21M
EBITDA Margin
-2030.10%
TTM Avg
-2765.29%
3Y Avg
-1907.45%
5Y Avg
-2238.98%
Market Cap
$3.14M
EBITDA Margin
-4291.67%
TTM Avg
-3563.06%
3Y Avg
-8274.29%
5Y Avg
-15578.54%
Market Cap
$3.07M
EBITDA Margin
-22711.52%
TTM Avg
-15924.10%
3Y Avg
-12940.13%
5Y Avg
-12940.13%
Market Cap
$3.50M
EBITDA Margin
3.53%
TTM Avg
-69.60%
3Y Avg
-286.97%
5Y Avg
-286.97%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Paranovus Entertainment Technology Ltd. (PAVS) | $3.28M | -7.62% | -10302.25% | -6471.31% | -3608.51% |
| Nexalin Technology, Inc. (NXL)vs › | $3.30M | -2774.55% | -3680.87% | -3159.91% | -3026.36% |
| MBody AI Ltd. (MBAI)vs › | $3.25M | N/A | N/A | N/A | N/A |
| Aethlon Medical, Inc. (AEMD)vs › | $3.21M | -2030.10% | -2765.29% | -1907.45% | -2238.98% |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.14M | -4291.67% | -3563.06% | -8274.29% | -15578.54% |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | N/A | N/A | N/A | N/A |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.07M | -22711.52% | -15924.10% | -12940.13% | -12940.13% |
| Eocene Ltd. (EOCN)vs › | $3.50M | N/A | N/A | N/A | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.50M | 3.53% | -69.60% | -286.97% | -286.97% |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.53M | N/A | N/A | N/A | N/A |
Gross Margin
16.5%
EBITDA Margin
-7.6%
Operating Margin
-23.1%
Net Margin
-87.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-03-31 | -71.50% |
| 2025-09-30 | 3.65% |
| 2025-03-31 | -30838.89% |
| 2024-09-30 | -1412.24% |
| 2023-03-31 | -37.58% |
| 2022-09-30 | -12.27% |
| 2022-03-31 | -83.03% |
| 2021-09-30 | -21.36% |
| 2021-03-31 | -3.38% |
| 2020-09-30 | 18.66% |
| 2020-03-31 | 17.55% |
| 2019-09-30 | 32.40% |
| 2019-03-31 | 36.29% |
| 2018-09-30 | 34.13% |
| 2018-03-31 | 31.33% |
| 2017-09-30 | 35.88% |
